Aktuellt
SENASTE
The NTAP reimbursement decision is distinctly positive, and the CMS decision enables clinics to use the three-year NTAP reimbursement rate of USD 97.50 per patient (a typical patient will require one test per admission) as of 1 October 2024. As a result, Q-linea’s ability to extend the US pipeline of clinical ASTar evaluations will become a more important value driver, and Q-linea’s prospects of securing US commercial partners are now improved.
LÄS MER
